Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIIb, Open-Label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor

NCT01667562 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01667562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01667562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIIb, Open-Label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
January 20, 2012
Completion date
September 7, 2017
Enrollment
375 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer